Mullen v. Wells Fargo & Company

CourtDistrict Court, N.D. California
DecidedMay 6, 2022
Docket3:20-cv-07674
StatusUnknown

This text of Mullen v. Wells Fargo & Company (Mullen v. Wells Fargo & Company) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Mullen v. Wells Fargo & Company, (N.D. Cal. 2022).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6

9 EMPLOYEES’ RETIREMENT SYSTEM OF THE STATE OF HAWAII, on behalf of itself 10 and similarly-situated individuals, No. C 20-07674 WHA

11 Plaintiff,

12 v.

13 WELLS FARGO & COMPANY, C. ALLEN ORDER RE MOTION TO DISMISS PARKER, TIMOTHY J. SLOAN, JOHN R. 14 SHREWSBERRY, PERRY PELOS, MARK 15 MYERS, and KARA MCSHANE,

16 Defendants.

17 18 INTRODUCTION 19 In this putative securities class action, defendants move to dismiss. To the extent stated, 20 defendants’ motion is GRANTED. 21 STATEMENT 22 Here follow the facts, as pleaded. At all material times, Wells Fargo & Company was a 23 financial services and bank holding company. Among other services, it originated commercial 24 real estate (CRE) loans to fund the purchase, remodeling, or refinancing of commercial 25 property, as well as commercial and industrial (C&I) loans to fund business operating expenses 26 (Amd. Compl. ¶ 51). In addition to originating commercial loans, Wells Fargo also bundled 27 and sold the right to collect on those loans, a process known as sponsoring a securitization (id. 1 Securities (CMBS), which star in the complaint (id. ¶ 53). Employees’ Retirement System of 2 the State of Hawaii invested in one or more Wells Fargo CMBS and serves as court-appointed 3 lead plaintiff in this putative class action. The putative class consists of persons or entities 4 damaged as a result of acquiring stock in commercial loans sponsored by Wells Fargo between 5 October 13, 2017, and October 13, 2020 (id. ¶ 1). The consolidated amended complaint asserts 6 claims against Wells Fargo and certain officers (id. ¶¶ 42–46). 7 The claims concern the ways in which Wells Fargo assessed the financial strength of its 8 commercial borrowers during loan origination. It further concerns assessment of the borrowers 9 whose existing loans Wells Fargo sponsored into a CMBS. The complaint “describes a 10 pervasive problem of lenders and securities issuers have [sic] regularly altered financial data 11 for commercial properties without justification to make the properties appear more valuable, 12 and borrowers more creditworthy, than they actually are.” The complaint incorporates articles 13 and studies that concerned the entire industry but also calls out information and trends specific 14 to Wells Fargo, which allegedly dominated the commercial lending industry (id. ¶¶ 87 (cleaned 15 up), 99, 100, 101, 111, 158, 159). 16 As stated, when it issued a loan, Wells Fargo evaluated borrowers’ ability to pay, as well 17 as the value of any property securing the loan (collateral), in order to determine the size of any 18 loan. Prior to sponsoring a loan into a CMBS, Wells Fargo similarly underwrote the existing 19 loan. As used herein, underwriting was this art of predicting a business’ future ability to pay. 20 “Wells Fargo’s process for originating and underwriting commercial mortgage loans” were 21 allegedly identical. Both included, among other things, evaluating credit, rent, operating 22 budgets, predicted future cash flow, and real property (sometimes using appraisers). Central 23 here, the “underwriting process” before CMBS sponsorship could include “adjustments” to a 24 borrower’s stated financial figures in order to accommodate the underwriter’s opinion about a 25 borrower’s long-term ability to pay (id. ¶¶ 106, 221; id. n.15; see also ¶¶ 73, 94, 106, 146, 152, 26 221–22, 225–31, 239). 27 Wells Fargo specialized in two major types of securitized commercial investment 1 types, and CMBSs, which contained only CRE mortgages. The complaint also notes that the 2 inflationary practices applied to all commercial lending, including loans to alternative asset 3 managers who in turn issued commercial loans using similar risky inflationary practices. 4 CMBS data availability makes Wells Fargo’s CMBS sponsorship the focus of the complaint, 5 however (Amd. Compl. ¶¶ 15, 19, 51–54, 152, 243). 6 Critical concepts in the complaint include: 7 • NOI was “total rent and other revenues minus general operating expenses like management, utilities, cleaning, repairs, and 8 maintenance” (id. ¶ 161). NOI was a key input that ultimately helped to determine the size of a loan that a business could 9 receive (id. ¶ 105).

10 • “Net Cash Flow (NCF) [was] NOI minus replacement of capital items such as building and tenant improvements, and leasing 11 commissions” (id. ¶ 161).

12 • Loan-to-value (LTV) ratio referred to the size of the loan relative to the value of the business (see id. ¶ 213). 13 • “[R]eserves, allowances, charge-offs, and other impairments” 14 referred to the capital Wells Fargo needed to hold in order to offset any loan that borrowers would not fully repay (see id. ¶¶ 15 21, 24, 256). 16 Between 2016 and 2019, Wells Fargo developed at least twenty-six CMBSs. The “deals” 17 were valued at between $192 million and $1.04 billion. Wells Fargo originated up to 48.9% of 18 the commercial loans that it bundled into CMBSs in this period. The remainder Wells Fargo 19 sponsored from other originators. A CMBS usually contained less than one hundred bundled 20 commercial loans, far fewer than the residential mortgage-backed securities made famous in 21 the financial crisis (id. ¶¶ 54, 231). 22 In 2019, the wholesale banking division provided 55% of Wells Fargo’s net income. As 23 of June 2020, C&I loans amounted to approximately $350 billion of Wells Fargo’s $513 24 billion commercial lending business. CRE loans comprised approximately $146 billion of the 25 same (id. ¶¶ 48, 51). 26 Defendants now move to dismiss. This order follows full briefing, oral argument 27 (telephonic due to COVID-19), and supplemental briefing. 1 ANALYSIS 2 When ruling on motions to dismiss brought under Section 10(b), “courts must, as with 3 any motion to dismiss for failure to plead a claim on which relief can be granted, accept all 4 factual allegations in the complaint as true.” Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 5 U.S. 308, 322 (2007). “Securities fraud class actions must,” however, “meet the higher, 6 exacting pleading standards of Federal Rule of Civil Procedure 9(b) and the Private Securities 7 Litigation Reform Act (PSLRA).” Oregon Pub. Employees Ret. Fund v. Apollo Grp. Inc., 774 8 F.3d 598, 604 (9th Cir. 2014). To state a claim under Section 10(b), a complaint must plead (i) 9 a material misrepresentation or omission; (ii) scienter; (iii) connection with the purchase or 10 sale of a security; (iv) reliance; (v) economic loss; and (vi) a causal connection between the 11 material misrepresentation and the loss. Dura Pharm., Inc. v. Broudo, 544 U.S. 336, 342 12 (2005). Defendants contest falsity, materiality, scienter, and loss causation (Br. i). 13 1. FALSITY. 14 Section 10(b) of the PLSRA prohibits fraud or deceit in connection with the sale of 15 securities. See In re VeriFone Holdings, Inc. Sec. Litig., 704 F.3d 694, 703 (9th Cir. 2012). 16 SEC Rule 10b-5 makes it illegal “[t]o make any untrue statement of a material fact or to omit 17 to state a material fact necessary in order to make the statements made, in the light of the 18 circumstances under which they were made, not misleading.” 17 C.F.R. § 240.10b-5(b). An 19 actionable “omission” must do more than leave out a fact. It must “affirmatively create an 20 impression of a state of affairs that differs in a material way from the” real one. Brody v. 21 Transitional Hosps.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Dura Pharmaceuticals, Inc. v. Broudo
544 U.S. 336 (Supreme Court, 2005)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
In Re Wells Fargo Securities Litigation
12 F.3d 922 (Ninth Circuit, 1993)
South Ferry LP, No. 2 v. Killinger
542 F.3d 776 (Ninth Circuit, 2008)
Jacksonville Police & Fire Pf v. Cvb Financial Corp
811 F.3d 1200 (Ninth Circuit, 2016)
Karim Khoja v. Orexigen Therapeutics, Inc.
899 F.3d 988 (Ninth Circuit, 2018)
Gompper v. Visx, Inc.
298 F.3d 893 (Ninth Circuit, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
Mullen v. Wells Fargo & Company, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mullen-v-wells-fargo-company-cand-2022.